Axxcess Wealth Management LLC Sells 440 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Axxcess Wealth Management LLC decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,390 shares of the company’s stock after selling 440 shares during the period. Axxcess Wealth Management LLC’s holdings in IDEXX Laboratories were worth $988,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. FSA Wealth Management LLC purchased a new position in IDEXX Laboratories during the 3rd quarter worth $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter worth about $38,000. Finally, Crews Bank & Trust purchased a new stake in IDEXX Laboratories in the 4th quarter valued at about $41,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $420.62 on Friday. The company has a market cap of $34.21 billion, a PE ratio of 39.42, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm’s 50-day simple moving average is $437.30 and its two-hundred day simple moving average is $445.53. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IDXX. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.